Press Release 365 : Next Generation Newswire August 28, 2014 Edition Welcome to Press Release 365!  
Login | Register | FAQs | Contact  

New Technology for Combating Hospital Acquired Infections

May 16, 2009
"SpectraCell can type over 100 samples in a single shift installed in a routine microbiological lab environment."

ROTTERDAM, THE NETHERLANDS -- Real time typing is considered key to identifying sources of hospital acquired infections and vectors of transmission within the hospital, but this much needed capability has been unavailable until today. River Diagnostics is filling this gap with the launch of its SpectraCell RATM Bacterial Strain Analyzer simultaneously at the 19th European Congress of Clinical Microbiology and Infectious Diseases and the 109th General Meeting of the American Society for Microbiology this week. The SpectraCell system, which has been designed for real time typing, provides a rapid epidemiologic assessment of hospital outbreaks for such pathogens as methicillin-resistant and sensitive Staphylococcus aureus, (MRSA/MSSA). 

Public health laboratories can benefit in the same way from the epidemiologic information, to pinpoint the sources of microbial contaminations in food products. SpectraCell can type over 100 samples in a single shift installed in a routine microbiological lab environment. Its discriminatory power matches that of genotyping methods such as pulsed field gel electrophoresis. SpectraCell typing is based on Raman spectroscopic analysis of bacterial biomass taken from an overnight culture. Results are available within one hour after culturing compared to two to five days for the current method and can easily be combined with historic data to enable in depth epidemiologic analyses. 

SpectraCell has been extensively validated for typing of clinical MRSA/MSSA and Acinetobacter spp. CoNS, E. faecium (incl VRE), Klebsiella, Enterobacter spp, Stenotrophomonas maltophilia, Pseudomonas spp, and food borne pathogens Salmonella, Shigella, E. coli, and Legionella are scheduled to follow in rapid succession this year.

The SpectraCell system consists of a Workstation for loading microbial samples onto a disposable optically precise MicroSlide sample carrier, the SpectraCell Analyzer, and an easy-to-use graphical user interface for instrument control and data analysis.

It will be on display in the River Diagnostics booths at the European Conference for Clinical Microbiology and Infectious Diseases in Helsinki (Finland) from May 16 to May 19, and at the American Society for Microbiology meeting in Philadelphia, PA (USA) from May 18 to May 20. 

About River Diagnostics:
River Diagnostics was founded in 2002 to develop and bring to market products for cell and tissue analysis based on Raman spectroscopy. This non-destructive optical technology provides detailed information about the molecular composition of cells and tissues, and can be applied both in vivo and ex vivo.

River Diagnostics' first product, introduced in 2004, is an instrument for non-invasive skin analysis, which has been readily adopted by the personal care industry for skin typing and product development. Clinical diagnostic applications are under development.

The company recently closed a successful Series B financing round, in which existing investors Erasmus Biomedical Fund BV en TechFund BV, new private investors, company management and employees have participated. The proceeds of the financing round will be used to optimally engage the very strong initial market interest in the SpectraCell system and to expand operations in the US through the company's wholly-owned subsidiary River Diagnostics, Inc.

For further information about SpectraCell please contact:
Michael Rumbin, Vice-President of Sales & Marketing
tel: 1-866-974-8373
tel : +31-61-586-4148
email: rumbin@riverd.com

For further information about River Diagnostics please contact:
Gerwin Puppels, Chief Executive Officer

tel: +31-10-2210720
email: puppels@riverd.com




Keywords: MRSA, Salmonella, hospital infections  Medical » Hospitals



Contact Info
  • River Diagnostics B.V.
  • Michael Rumbin
  • +31 61-586-4148
Disclaimer